The relationship between gut microbiota, immunoglobulin A, and vaccine efficacy
Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine, a ...
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range ...
Mirage News4d
Gut Microbiota, Immunoglobulin Boost Vaccine Success
Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine-a bacterium that can cause ...
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...
Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy
Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile.
News Medical on MSN4d
Gut microbiota impacts pneumococcal vaccine response in immunodeficient individuals
Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine-a bacterium that can cause various diseases, such as pneumonia.
European Medical Journal3d
Novel Oral Norovirus Vaccine Shows Strong Immune Response
A new orally administered norovirus vaccine tablet has demonstrated promising safety and immunogenicity in older adults.
Biohaven reports ‘positive’ data from study of BHV-1300
Biohaven (BHVN) highlighted the success of BHV-1300, its potential first-in-class IgG selective degrader, in achieving rapid and deep ...